- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To demonstrate the superiority in overall survival of ODM-201 in addition to standard androgen deprivation therapy (ADT) and docetaxel over placebo in addition to standard ADT and docetaxel
Critère d'inclusion
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)